Unlike the m6A modulators mentioned previously, IGF2BP3 has been proven to be secreted into serum and could be a promising diagnostic and prognostic marker of prostate cancer and renal cell carcinoma.12, 13. This evidence concerns the gene IGF2BP3 and prostate cancer.